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Abstract 
Phospholipases A2 generate lipid mediators that constitute an important component of the 
integrated response of macrophages to stimuli of the innate immune response. Since these cells 
contain multiple phospholipase A2 forms, the challenge is to elucidate the roles that each of these 
forms play in regulating normal cellular processes and in disease pathogenesis. A major issue is 
to precisely determine the phospholipid substrates that these enzymes utilize for generating lipid 
mediators. There is compelling evidence that group IVA cytosolic phospholipase A2 (cPLA2α) 
targets arachidonic acid-containing phospholipids but the role of the other cytosolic enzyme 
present in macrophages, namely the Ca2+-independent group VIA phospholipase A2 (iPLA2β) 
has not been clearly defined. We have applied mass spectrometry–based lipid profiling to study 
the substrate specificities of these two enzymes during inflammatory activation of macrophages 
with zymosan. Using selective inhibitors, we find that, contrary to cPLA2α, iPLA2β spares 
arachidonate-containing phospholipids and hydrolyzes only those that do not contain 
arachidonate. Analyses of the lysophospholipids generated during activation reveal that the 
major species produced, LPC(16:0) is generated by iPLA2β with minimal or no involvement of 
cPLA2α. The other major species produced, LPC(18:0) is generated primarily by cPLA2α. 
Collectively, these findings suggest that cPLA2α and iPLA2β act on different phospholipids 
during zymosan stimulation of macrophages, and that iPLA2β shows a hitherto unrecognized  
preference for choline phospholipids containing palmitic acid at the sn-1 position that could be 
exploited for the design of selective inhibitors of this enzyme with therapeutic potential.  
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Introduction 
Macrophages contain large amounts of arachidonic acid (AA)3 esterified in membrane 
glycerophospholipids [1-3], which makes them a major source of eicosanoids during innate 
immune reactions. The eicosanoids affect immune regulation by modulating phagocyte cell 
activation at different points, including differentiation and migration, phagocytic capacity, and 
cytokine production [4-7].   
The first committed step in the synthesis of eicosanoids is the phospholipase A2 (PLA2)-
mediated cleavage of phospholipids to release free AA [8]. There are multiple PLA2 enzymes in 
cells, and many of them are potentially capable of catalyzing the release of AA from membrane 
phospholipids [8-11]. Based on biochemical commonalities, mammalian PLA2 enzymes can be 
classified into five major families, namely the Ca2+-dependent secreted PLA2s, the Ca
2+-
dependent cytosolic PLA2s, the Ca
2+-independent cytosolic PLA2s,  the platelet-activating factor 
acetyl hydrolases, and the lysosomal PLA2s [11]. Of these, the first two have been repeatedly 
implicated in AA mobilization in response to a variety of immunoinflammatory stimuli [8-11]. 
Today, there is general agreement that Ca2+-dependent cytosolic group IVA PLA2 (cPLA2α) is 
the critical enzyme in AA release and that, depending on the agonist, a secreted PLA2, in 
particular that belonging to groups IIA, V and X, may also participate by amplifying the 
cPLA2α-regulated response [8-11].  
Regarding the other cytosolic PLA2 form present in macrophages, i.e., the Ca
2+-
independent group VIA PLA2 (iPLA2β) [11], no evidence has been provided for its involvement 
in eicosanoid production under innate immunity and inflammation conditions, as manifested by 
studies in murine mesangial cells [12], murine peritoneal macrophages [13, 14], murine P388D1 
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and RAW264.7 macrophage-like cells [15-18], human neutrophils [19, 20], human monocytes 
[21] and human U937 promonocytic cells [22, 23], where selective inhibition of  iPLA2β did not 
modify the stimulus-induced AA release. However iPLA2β is emerging as an important enzyme 
during stimulus-response coupling, and a variety of roles have been ascribed to this enzyme in 
various cells and tissues [24-27]. In this regard, iPLA2β may play major roles in intracellular 
signaling cascades, in particular those regulating phospholipid hydrolysis during  apoptosis [26-
31].  
In recent work we have extensively investigated the mechanisms of PLA2-mediated AA 
mobilization in monocytes and macrophages in response to a variety of innate immune stimuli. 
In these studies, we have taken advantage of the use of mass spectrometry-based lipidomic 
approaches to define at a molecular species level the sources of AA liberation and incorporation 
[32-38]. In this work we have applied a similar approach to relate changes in phospholipid 
turnover with the activation of particular PLA2 forms, namely cPLA2α and iPLA2β. For this 
purpose, we have used selective inhibitors of each of these forms. The use of inhibitors to 
address the role of intracellular PLA2s during cell activation has a number of advantages over 
other widely used methods, such as siRNA or cells from knockout mice, in that inhibition 
develops rapidly, which reduces the impact of unspecific effects that could come up with time, 
and the absence of compensations that might obscure the interpretation of results [39]. Our data 
show that cPLA2α and iPLA2β act on different phospholipid pools, thereby regulating separate 
pathways, one leading to AA mobilization and the other to lysoPC molecules containing palmitic 
acid at the sn-1 position (LPC(16:0)), respectively. These studies suggest a critical role, not only 
for cPLA2α, but also for iPLA2β in the intracellular signaling cascades initiated by innate 
immune receptors and its functional role in the generation of  inflammatory lipid mediators. 
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Materials and Methods 
Reagents  
Cell culture medium was from Molecular Probes-Invitrogen (Carlsbad, CA). Chloroform and 
methanol (HPLC grade) were from Fisher Scientific (Hampton, NH). Lipid standards were from 
Avanti Polar Lipids (Alabaster, AL) or Larodan Fine Chemicals (Malmö, Sweden). The cPLA2α 
inhibitor pyrrophenone [40] was synthesized and provided by Dr. A. Llebaria (Institute for 
Chemical and Environmental Research, Barcelona, Spain). The iPLA2β inhibitor FKGK18 
(1,1,1-trifluoro-6-(naphthalen-2-yl)hexan-2-one) was synthesized as previously described [41]. 
The CoA-independent transacylase inhibitor SK&F98625 (diethyl 7-(3,4,5-triphenyl-2-oxo-2,3-
dihydroimidazol-1-yl)heptane phosphonate) [42-44] was synthesized and provided by Dr. A. 
Pérez (Department of Organic Chemistry, University of Valladolid). All other reagents were 
from Sigma-Aldrich.  
 
Cell culture 
Resident peritoneal macrophages from Swiss male mice (University of Valladolid Animal 
House, 10–12 wk old) were obtained by peritoneal lavage using 5 ml cold PBS, as described 
elsewhere [45, 46]. The cells were plated at 2 x 106 per well (6-well plates) in 2 ml RPMI 1640 
medium with 10% heat-inactivated serum, 100 U/ml penicillin, and 100 mg/ml streptomycin, 
and allowed to adhere for 20 h in a humidified atmosphere of 5% CO2 at 37°C. Wells were then 
extensively washed with PBS to remove nonadherent cells. Adherent macrophages were then 
used for experimentation. When inhibitors were used, they were added to the incubation media 
30 min before stimulating the cells with zymosan. All procedures involving animals were 
undertaken in accordance with the Spanish National Committee on Biosafety and Animal Care, 
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under the guidelines established by the Spanish Ministry of Agriculture, Food, and Environment, 
and the European Union.  
 
Preparation  of  zymosan 
Zymosan particles were suspended in PBS, boiled for 60 min, and washed three times. The final 
pellet was resuspended in PBS at 20 mg/ml and stored frozen. Zymosan aliquots were diluted in 
serum-free medium and sonicated before addition to the cells. No endogenous PLA2 activity was 
detected in the zymosan batches used in this study, as assessed by in vitro assay under a variety 
of conditions [47,48].  
 
Liquid chromatography/mass spectrometry analyses of macrophage glycerophospholipids 
A cell extract corresponding to 107 cells was used for these analyses. The following internal 
standards were added: 600 pmol each of 1,2-dipentadecanoyl-sn-glycero-3-phosphocholine, 1,2-
dilauroyl-sn-glycero-3-phosphoethanolamine, and 1,2-dipalmitoyl-sn-glycero-3-phosphoinositol, 
before lipid extraction according to the method of Bligh and Dyer [49]. After evaporation of 
organic solvent under vacuum, the lipids were redissolved in 100 µl methanol/water (9:1, v/v) 
and injected into a high-performance liquid chromatograph equipped with a binary pump Hitachi 
LaChrom Elite L-2130 and a Hitachi Autosampler L-2200 (Merck). The column was a 
Supelcosil LC-18 (5-mm particle size, 250 x 2.1 mm) (Sigma-Aldrich) protected with a 
Supelguard LC-18 (20 x 2.1 mm) guard cartridge (Sigma-Aldrich). Mobile phase was a gradient 
of solvent A (methanol/water/n-hexane/32% ammonium hydroxide, 87.5:10.5:1.5:0.5, by vol.) 
and solvent B (methanol/n-hexane/32% ammonium hydroxide, 87.5:12:0.5, by vol.). The 
gradient was started at 100% solvent A; it was decreased linearly to 65% solvent A, 35% solvent 
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B in 20 min, to 10% solvent A, 90% solvent B in 5 min, and to 0% solvent A, 100% solvent B in 
an additional 5 min. Flow rate was 0.5 ml/min, and 80 µl of the lipid extract was injected. The 
liquid chromatography  system was coupled online to a Bruker esquire6000 ion-trap MS (Bruker 
Daltonics, Bremen, Germany). The total flow rate into the column was split and 0.2 ml/min 
entered into the electrospray interface of the mass spectrometer. Nebulizer gas was set to 30 
pounds per square inch, dry gas to 8 l/min, and dry temperature to 365°C. Ethanolamine 
phospholipids (PE) and phosphatidylinositol (PI)  were detected in negative ion mode with the 
capillary current set at +3500 V over the initial 25 min as [M–H]– ions. Choline phospholipid 
(PC) species were detected over the elution interval from 25 to 35 min in positive ion mode, as 
[M+H]+ ions, with the capillary current set at –3500 V.  
PE and PI molecular species were identified by multiple reaction monitoring MS/MS 
experiments on chromatographic effluent by comparison with previously published data [32-38]. 
Cutoff  parameter was set at m/z 150 and fragmentation amplitude at 1 arbitrary unit. Because of 
the lability of vinyl ether linkages in acid media, plasmanyl (1-alkyl) and plasmenyl (1-alk’1’-
enyl) glycerophospholipids were distinguished by acidifying the samples before lipid extraction. 
For the identification of acyl chains of PC species, ionization was carried out in negative mode 
with postcolumn addition of acetic acid at a flow rate of 100 ml/h as [M+CH3CO2]
 –  adducts, 
and acyl chains were identified by MS3 experiments. Stereospecific assignation of fatty acyl 
chains was carried out by comparing the relative intensities of the 1-lysophospholipid and 2-
lysophospholipid compounds arising in the fragmentation experiments (the signal of the latter 
predominates over that of the former in ion-trap MS) [32-38].  
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Liquid chromatography/mass spectrometry analyses of lysophospholipids 
A cell extract corresponding to 107 cells was used for these analyses. The following internal 
standards were added: 200 pmol each of 1-tridecanoyl-sn-glycero-3-phosphocholine and 1-
miristoyl-sn-glycero-3-phosphoethanolamine, before lysophospholipid extraction with n-butanol. 
After evaporation of the organic solvent under vacuum, the lipids were redissolved in 100 µl 
methanol/water (9:1, v/v) and injected into a high-performance liquid chromatograph equipped 
with a binary pump Hitachi LaChrom Elite L-2130 and a Hitachi Autosampler L-2200 (Merck). 
The column was a Supelcosil LC-Si protected with a Supelguard LC-Si guard cartridge (Sigma-
Aldrich). Mobile phase was a gradient of solvent A (chloroform/methanol/water/32% 
ammonium hydroxide, 75:24:5:0.5, by vol.) and solvent B (chloroform/methanol/water/32% 
ammonium hydroxide, 55:39:5.5:0.5, by vol.). The gradient was started at 100% solvent A, it 
was decreased linearly to 50% solvent A in 2 min, it was maintaned for 8 min, and finally it was 
decreased to 0% solvent A in 2 min. Flow rate was 0.5 ml/min, and 80 µl of the lipid extract was 
injected. The liquid chromatography  system was coupled online to a Bruker esquire6000 ion-
trap MS (Bruker Daltonics, Bremen, Germany). The total flow rate into the column was split and 
0.2 ml/min entered into the electrospray interface of the mass spectrometer. Nebulizer gas was 
set to 30 pounds per square inch, dry gas to 8 l/min, and dry temperature to 365°C. Ethanolamine 
and inositol lysophospholipids were detected in negative ion mode with the capillary current set 
at +3500 V as [M–H]– ions. Choline lysophospholipids were detected in positive ion mode as 
[M+H]+ ions, with the capillary current set at –4000 V. Quantification of inositol 
lysophospholipid species was carried out by comparison with an external calibration curve made 
with 1-palmitoyl-sn-glycero-3-phosphoinositol. 
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Liquid chromatography/mass spectrometry analyses of eicosanoids 
A small amount of butylated hydroxytoluene in methanol (0.01%, w/v) was added to the 
supernatants to prevent eicosanoids degradation. Deuterated PGE2 and LTB4 (400 pmol each) 
were added as internal standards before extraction. Eicosanoids were extracted using Bond Elut 
Plexa solid phase extraction columns (Agilent), following the manufacturer’s instructions. 
Columns were pretreated with 3 ml methanol and 3 ml water. Supernatants were acidified with 
0.5% acetic acid and 10% methanol was also added before sample loading. Samples were 
washed with 3 ml 10% methanol and lipid products were eluted with 1.5 ml 100% methanol 
twice. Lipid products were concentrated under vacuum and redissolved in 100 µl of solvent A 
(see below). 
 90 µl of the extract was injected into an Agilent 1260 Infinity high-performance liquid 
chromatograph equipped with an Agilent G1311C quaternary pump and an Agilent G1329B 
autosampler. The column was a Supelcosil LC-18 (250 x 2.1 mm, 5 µm particle size) protected 
with a Supelguard LC-18 (20 x 2.1 mm) guard cartridge (Sigma-Aldrich). Eicosanoids were 
separated according to the procedure described by Dumlao et al. [50] with minor modifications. 
Briefly, the mobile phase consisted of a gradient of solvent A (water/acetonitrile/acetic acid, 
70:30:0.02, by vol) and solvent B (acetonitrile/isopropanol, 50:50, by vol). The gradient was 
started at 100% solvent A, which was decreased linearly to 75% at 3 min, 55% at 11 min, 40% at 
13 min, 25% at 18 min, and 10% at 18.5 min. The last solvent mixture was held for an 
addditional 1.5-min period, and finally the column was reequilibrated with 100% solvent A for 
10 minutes before the next sample injection. 
 The flow rate through the column was fixed at 0.6 ml/min and this flow entered into the 
electrospray interface of an API2000 triple quadrupole mass spectrometer (Applied Biosystems). 
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The parameters of the source were set as follows: ion spray voltage, -4500 V; curtain gas, 25 
pounds per square inch; nebulizer gas, 40 pounds per square inch; desolvation gas, 80 pounds per 
square inch; temperature, 550°C. The analyzer mode was set to scheduled multiple-reaction 
monitoring with negative ionization, defining for each analyte the m/z of the parent ion as Q1 
mass, the m/z of its daugther ion fragment (transition) as Q3 mass, and associating it to the 
chromatograpic retention time to improve the numer of analytes collected in a single 
chromatograpic run. The retention time window was set to 120 s. The declustering potential and 
collision energy for each analyte was optimized by the use of analytical standards. Other 
parameters were fixed for all analytes: entrance potential, -10 V; focusing potential, -350 V; 
collision cell exit potential, -10 V. Quantification was carried out by integrating the 
chromatographic peaks of each species and comparing with an external calibration curve made 
with analytical standards. 
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Results 
AA-containing species in macrophages  
The profile of AA-containing glycerophospholipid species of peritoneal macrophages was 
measured by liquid chromatography/ion-trap MS and the results are shown in Fig. 1. The lipids 
were unequivocally identified by determining the production of an m/z 303 fragment in MSn 
experiments, which corresponds to AA. Structural identification of the glycerophospholipids was 
achieved by looking at the fragments and/or neutral losses obtained in MS2 experiments (PE, PI) 
or MS3 (PC) [32-38]. Fatty chains within the different phospholipid species are designated by 
their number of carbons:double bonds. A designation of O- before the first fatty chain indicates 
that the sn-1 position is ether-linked, whereas a P- designation indicates a plasmalogen form (sn-
1 vinyl ether linkage) [51]. In agreement with previous observations from this [38] and other 
laboratories [2, 52], we found that most of the AA was found in PE species (32.8 nmol/mg 
protein), followed by PC (25.9 nmol/mg protein) and PI (10.3 nmol/mg protein). Regarding 
molecular species, the major AA-containing ones were: PE(P-16:0/20:4), PC(16:0/20:4), PE(P-
18:0/20:4), PI(18:0/20:4), PE(18:0/20:4), and PC(18:0/20:4), again in agreement with previous 
estimates [38]. Stimulation of the cells with the phagocytosable particle zymosan promoted 
marked changes in the content of cellular AA-containing phospholipids (Fig. 1). All major AA-
containing PC species decreased, and so did PI(18:0/20:4). However the PE species remained 
unchanged (Fig. 1). These changes were fully prevented when the incubations were carried out in 
the presence of the well-established cPLA2α inhibitor pyrrophenone (Fig. 1). 
 In parallel studies we also determined the effect of inhibiting iPLA2β with the novel 
selective inhibitor FKGK18 [41]. In stark contrast with the experiments using pyrrophenone, the 
zymosan-stimulated decreases in PC and PI molecular species were the same whether or not 
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FKGK18 was present in the incubations (Fig. 1). Thus the data suggest that AA-containing 
phospholipids are hydrolyzed by cPLA2α but not by iPLA2β in zymosan-stimulated 
macrophages.  
 The above results were conducted after 1 h stimulation with zymosan, as AA release in 
response to this agonist is maximal at that time [15, 53]. However, since at later times COX-2 is 
upregulated and prostaglandins are most robustly produced, we also examined the distribution of 
AA-containing phospholipid species at these later time points (8 h). The results indicated no 
further differences in phospholipid turnover beyond those already observed at 1 h (Fig. 1), thus 
confirming that the bulk of AA mobilization in response to zymosan occurs at early stimulation 
times (data not shown). 
Role of AA-containing PE species 
The finding that the levels of all AA-containing PE species do not appreciably change during 
zymosan stimulation, despite them constituting the major cellular reservoirs of AA, is striking 
and deserved further investigation. AA is known to be incorporated into PE species by the Lands 
cycle but also via a transacylation reaction which uses AA-containing PC as donor and occurs in 
a CoA-independent manner [54]. This reaction proceeds at a very slow rate in resting cells, but is 
activated in receptor-stimulated cells as a part of a phospholipid remodeling pathway that seems 
to be necessary for a full AA mobilization response [54]. Thus we hypothesized that AA-
containing PE formation via CoA-independent transacylation could be taking place in zymosan-
stimulated macrophages and this would account for the apparent lack of AA-containing PE 
hydrolysis under these conditions.  To study this possibility we conducted experiments utilizing 
the well-established CoA-independent transacylase inhibitor SK&F98625 [42, 43]. This inhibitor 
was designed on the basis of analogy with compounds that inhibit acyl-CoA:cholesterol 
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acyltransferase, and has been found to potently block the movement of AA to PE in a variety of 
cells [42-44].  Preliminary determinations confirmed that at 10 µM, SK&F98625 quantitatively 
blocked the transfer of AA from PC to PE in RAW264.7 macrophage-like cells and peritoneal 
macrophages, and exerted only little inhibitory effect (<15%) on the Ca2+-dependent PLA2 
activity of a macrophage homogenate, as measured in vitro under a variety of conditions (data 
not shown).  Fig. 2 shows that in the presence of SK&F98625, the zymosan-stimulated cells did 
show significant decreases in the content of all major AA-containing PE species. 
Correspondingly, the levels of AA-containing PC species were preserved in the SK&F98625-
treated cells (Fig. 2). Collectively, these results demonstrate that AA-containing PE species are 
indeed hydrolyzed during zymosan-stimulation of the macrophages. In turn, the data also suggest 
that a major portion of the AA lost from PC (Fig. 1) is not released as free fatty acid but rather 
channeled to PE (Fig. 2).  
 The effect of SK&F98625 on the production of eicosanoids by the zymosan-stimulated 
cells is shown in Fig. 3. In agreement with previous observations [1], PGE2 was the largest    
eicosanoid produced under these conditions, and the presence of SK&F98625 reduced its 
formation by approx 30-40% (Fig. 3A). Similar decreases were also observed for the other 
cyclooxygenase metabolites measured, namely PGI2 (measured as 6-keto PGF1α), PGF2α, TXA2 
(measured as TXB2), and 11-HETE (Fig. 3A). This general decrease in prostanoid production 
when AA transfer from PC to PE is blocked by SK&F98625 was not unexpected, since this 
compound is known to reduce stimulus-induced AA mobilization in variety of cells [54], and our 
preliminary studies confirmed that this is also the case in zymosan-stimulated macrophages, 
where SK&F98625 reduced AA release by about 25-30%, as measured by gas 
chromatography/mass spectrometry. Importantly however, production of lipoxygenase 
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metabolites was strongly increased in cells treated with SK&F98625 (Fig. 3B), thus suggesting 
that the transfer of AA from PC to PE also serves to modulate the relative amount of 
lipoxygenase products formed. 
Profiling of phospholipid species not containing AA in macrophages 
Liquid chromatography/MS analyses of major phospholipid species not containing AA were 
conducted next, and the results are shown in Fig. 4. Because in many cases fragmentation of the 
m/z peaks detected in MS analyses yielded fragments corresponding to various species, it was 
not always possible to unequivocally assign structures to these m/z peaks. Thus, the data are 
given in abbreviated form, indicating phospholipid class and number of carbon atoms and double 
bonds of the two lateral chains together.  
A number of PC species was found to significantly decrease after zymosan activation of 
the cells, thus indicating that the stimulus also activates phospholipid hydrolytic pathways 
unrelated to eicosanoid signaling (Fig. 3A). The species that decreased most prominently were 
PC(32:0),  PC(34:2),  PC(34:1), PC(36:3), PC(36:2), PC(36:1), and PC(38:3). When the 
zymosan stimulations were conducted in the presence of pyrrophenone, the levels of all PC 
species remained essentially the same as those found in the absence of the inhibitor. Thus under 
zymosan activation conditions in intact cells, cPLA2α does not hydrolyze phospholipid 
substrates that do not  contain AA. This is an important observation, since although cPLA2α 
shows marked preference for AA-containing phospholipids in in vitro assays, such preference is 
not absolute and the enzyme also hydrolyzes phospholipid substrates that contain other fatty 
acids instead of AA in the sn-2 position in vitro [11].  
Conversely,  the use of the iPLA2β inhibitor FKGK18 did restore the levels of some of 
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the PC species up to levels found in unstimulated  cells (Fig. 4A). The most prominent effects 
were found in the two major species measured, namely PC(32:0) and PC(34:1), the levels of 
which were completely restored in the presence of FKGK18. These two species could be 
identified as PC(16:0/16:0) and PC(16:0/18:1) in fragmentation experiments. Minor species 
whose hydrolysis was completely prevented by FKGK18 were PC(32:1) and PC(34:2), and these 
could also be identified by fragmentation experiments as PC(16:0/16:1) and PC(16:0/18:2). It is 
therefore striking that four phospholipids unequivocally identified as iPLA2β substrates during 
zymosan activation, all contain palmitic acid (16:0) esterified at the sn-1 position. This finding 
strongly suggests that in activated cells iPLA2β displays some sort of specificity for PC 
molecules containing palmitic at the sn-1 position and, by inference, that lysoPC molecules 
containing sn-1 palmitic acid could serve a biological role. 
Figure 4B shows that zymosan induced no significant changes in the levels of PE species 
that do not contain AA, and that the presence of either pyrrophenone or FKGK18 along with 
zymosan did not produce any effect. With regard to PI species not containing AA, quite 
significant increases in the mass of some of them were detected, particularly PI(34:1) and 
PI(36:0) (Fig. 4C).  Neither pyrrophenone nor FKGK18 exerted significant effects on the levels 
of these PI species. We speculate that these increases may be consequent on the activation of the 
PI cycle leading to sustained supply of phosphatidylinositol 4,5-bisphosphate to generate calcium 
signals during zymosan stimulation of the macrophages [55, 56]. Fragmentation experiments 
indicated that PI(34:1) was a mix of PI(18:0/16:1) plus PI(16:0/18:1), and PI(36:0) was 
PI(18:0/18:0).  
 
 
16 
 
Profiling of lysophospholipid species in macrophages 
To obtain a more complete picture of the changes occurring via PLA2-mediated deacylation 
reactions in zymosan-stimulated macrophages, measurement of lysophospholipid species were 
also carried out, and the effects of pyrrophenone and FKGK18 were studied as well. The profile 
of lysoPC species generated after zymosan stimulation of the macrophages is shown in Fig. 5A. 
In general there was a good correlation between the appearance of lysoPC species and the 
disappearance of phospholipids shown in Figs. 1 and 4. Major lysoPC species detected were 
LPC(16:0) and LPC(18:0). When the effects of pyrrophenone and FKGK18 were examined,  a 
few interesting findings could be appreciated. Pyrrophenone inhibited formation of both 
LPC(16:0) and LPC(18:0) in the zymosan-stimulated cells, albeit inhibition of the latter was 
stronger than that of the former. These results correspond well with the data shown in Fig. 1A 
indicating that palmitic acid- and stearic acid-containing PC species are the major contributors to 
AA release in the activated cells. Conversely, FKGK18 strongly inhibited LPC(16:0) formation 
but exerted little effect on LPC(18:0) formation (Fig. 5A). Again, these data correspond well 
with the data of Fig. 4A suggesting that iPLA2β shows selectivity for PC species containing 
palmitic acid at the sn-1 position. Collectively, these results suggest that, while both cPLA2α and 
iPLA2β contribute to lysoPC accumulation during stimulation of the cells with zymosan, 
LPC(18:0) appears to be produced primarily by cPLA2α, while LPC(16:0) appears to be 
produced primarily by iPLA2β. 
Regarding other lysophospholipid species, no increases in lysoPE were detected under 
any condition (Fig. 5B). Decided increases in lysoPI species were detected, which could be 
abrogated by pyrrophenone but not by FKGK18, suggesting that lysoPI production in activated 
cells is primarily linked to AA mobilization (cf. Fig. 5C and Fig. 1C). 
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Role of lysoPC species produced by zymosan-stimulated macrophages 
It is well established that not all of the AA liberated following cellular stimulation is converted 
into biologically-active eicosanoids, but a significant portion of the free AA is reincorporated 
back into phospholipids by the action of CoA-dependent acyltransferases [8, 54]. While it has 
been described that this free AA that returns to phospholipids is incorporated primarily into PC 
[57], the exact molecular species involved have not been identified. To study the phospholipid 
species that reincorporate the AA during zymosan activation of the macrophages, a liquid 
chromatography/MS/MS metabolipidomic approach using [2H]AA to label the acceptors 
involved was utilized. This procedure consists in incubating the cells with [2H]AA at the time 
they are stimulated with zymosan. We have recently employed this technique to identify novel 
AA-containing inositol phospholipids in human monocytes and murine macrophages [32, 38]. 
Newly synthesized [2H]AA-containing phospholipids were unequivocally identified by their 
bell-shaped isotopic distribution with a maximum at +8 m/z apart from their native counterparts, 
due to the [2H]AA isotopomers. Fig. 6 shows the phospholipid species that incorporated [2H]AA 
after a 30-min incubation of the cells with zymosan in the presence of the fatty acid. The most 
abundant species, accounting for approx. 85-90% of total [2H]AA incorporated, were 
PC(16:0/[2H]AA) and PC(18:0/[2H]AA). This finding was not unexpected given the previous 
data showing that LPC(16:0) and LPC(18:0) were the major lysoPC species in zymosan-treated 
cells (Fig. 5A). Low amounts of other species were also produced, namely PC(18:1/[2H]AA) and 
three PI molecular species. No incorporation of [2H]AA into PE species was observed (Fig. 6).  
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Discussion 
Macrophages, like most mammalian cells, express the two major cytosolic PLA2 forms, i.e. 
cPLA2α and iPLA2β. While the role of cPLA2α as the rate-limiting provider of free AA release 
for eicosanoid synthesis in macrophages and other cells is well established [8-11], the cellular 
role of iPLA2β has not been clearly defined. Initially described as a homeostatic enzyme 
involved in phospholipid fatty acid remodeling [58-60], more recent data have suggested that the 
enzyme also plays multiple roles in activated cells, highlighting its potential as a therapeutic 
candidate for a number of pathophysiological conditions. [24-27, 61]. In this work, we aimed at 
both defining and differentiating the contribution of these two PLA2s to zymosan-stimulated 
phospholipid turnover in macrophages. We find that both enzymes act on different phospholipid 
substrates during zymosan stimulation. Our key findings can be summarized as follows: (i) 
cPLA2α targets AA-containing phospholipids and appears not to hydrolyze phospholipids that do 
not contain AA; (ii) iPLA2β does not hydrolyze AA-containing phospholipids during zymosan 
activation; (iii) iPLA2β appears to specifically target phospholipids carrying palmitic acid in the 
sn-1 position to generate LPC(16:0), which is a major acceptor for AA incorporation back into 
phospholipids; (iv) AA is released not only from PC and PI, but also from PE species; the 
amount of AA in PE is restored by the action of transacylation mechanisms using various PC 
species as donors; and (v) the loss of AA from PC as a consequence of zymosan-activation is a 
composite of the direct hydrolytic attack of cPLA2α and the transfer of AA to PE molecules. 
Taken together, the data presented here demonstrate the diversity of phospholipid pathways that 
operate in macrophages as well as their independent but converging regulation, which allows the 
cells to orchestrate tightly integrated responses during stimulation. On one hand there is a 
pathway that culminates in AA mobilization which involves the participation of cPLA2α and 
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CoA-independent transacylation reactions that remodel the various AA pools and, on the other 
hand, there is a phospholipid hydrolytic pathway that operates on phospholipid pools that do not 
contain AA but serves to generate high amounts of  palmitate-containing lysoPC, which in turn 
can be used to reincorporate part of the free AA which was liberated via cPLA2α-mediated 
reactions. This can be envisioned as a way to protect against excessive eicosanoid production 
during inflammation. In addition, iPLA2β-derived lysoPC may serve other biological roles as 
well. For example, this molecule has also been described to be antigenic for natural IgM 
antibodies, to constitute a ligand for C-reactive protein, and to act as a “find me” signal to attract 
phagocytes to migrate toward phagocytic targets [29-31]. The novel finding that iPLA2β shows 
specificity for palmitic acid-containing choline phospholipids and does not participate in AA 
release may have implications for the development of strategies for therapeutic intervention 
against different pathophysiological responses of the macrophages.  
The use of cell-permeable inhibitors to comparatively study the functioning of different 
PLA2 forms in cells has the key advantage that inhibition is achieved very rapidly, within 
minutes of addition to the cells. Thus, effects on transcription, translation or other long-term 
alterations of gene expression, which often occur with genetic strategies such as siRNA 
knockdown or gene knockout, are avoided. Another potential problem with genetic strategies, 
which the use of chemical inhibitors also avoids, is the existence of compensatory mechanisms 
arising from the expression of multiple related PLA2 isoforms in a cell or tissue. This can be 
exemplified by the strong body of evidence suggesting a role for cPLA2α in regulating 
tubulation and intra-Golgi transport, yet these processes function normally in fibroblasts from 
cPLA2α knockout mice [39, 62]. Also, we have repeatedly noted that inhibition of iPLA2β in 
phagocytic cells of various origins results in slowed cellular utilization of AA presumably due to 
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acute reduction of lysoPC levels [58-60, 63, 64]; however this effect is not observed in 
macrophages from iPLA2β knockout mice, which show normal lysoPC levels [14]. Finally, it has 
been appreciated that skeletal muscle from mice lacking group VIB phospholipase A2 —a Ca
2+-
independent PLA2 form with similarities to iPLA2β— by genetic ablation shows increased levels 
of both cPLA2α and iPLA2β [65]. 
Another advantage of the use of inhibitors stems from the recent discovery that some 
phospholipases, in addition to acting as enzymes, may also exert other important non-catalytic 
functions in cells. These functions would be lost if inhibition was accomplished by genetic 
approaches, but not if chemical inhibitors were used. In this regard, recent data have shown that, 
during phagocytosis, cPLA2α translocates to the site of nascent phagosomes to modulate the 
phagocytic process in a manner that is independent of its enzymatic activity [66]. Of course, the 
use of chemical inhibitors has its own issues such as the lack of specificity, and we acknowledge 
this as a limitation of the current study. It should be noted in this regard that the two inhibitors 
used in this work, pyrrophenone and FKGK18, are the most potent and selective inhibitors 
currently available to block cPLA2α and iPLA2β in cells. Pyrrophenone potently and selectively 
inhibits cPLA2α activity using a number of different in vitro lipolysis assays without detectable 
effects on other PLA2 activities, blocks AA release in mammalian cells in the 0.01-1 µM range 
[40, 67, 68], and has also been shown to be effective in experimental models of disease involving 
cPLA2α, such as collagen-induced arthritis and experimental autoimmune encephalomyelitis [11, 
39]. We have also shown that at the concentrations utilized in this study (1 µM), the inhibitor 
blocks essentially all measurable Ca2+-dependent PLA2 activity of  cell homogenates leaving 
unchanged the Ca2+-independent activity [47, 67, 69]. FKGK18, a member of  a family of 
polyfluoroketone-containing compounds, is the most potent iPLA2β inhibitor yet reported, 
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completely blocking iPLA2β activity at concentrations at least 200 times lower than those 
required for inhibition of other PLA2 activities, which makes it a valuable tool to explore the role 
of iPLA2β in cells and in vivo models [11, 41].  In keeping with this observation, very recent 
data in pancreatic beta-cells show that FKGK18 blocks iPLA2β-mediated responses in these cells 
while leaving unchanged the cPLA2α-dependent ones [70]. Moreover, at the concentrations used 
in this study (1 µM), FKGK18 completely inhibited the Ca2+-independent PLA2 activity of 
macrophage homogenates while exerting no effect on the Ca2+-dependent activity as measured 
under a variety of assay conditions. Together, all these control measurements provide confidence 
on the specificity of the inhibitors employed in this study, yet the existence of unknown targets 
that could obscure interpretation of the results is a possibility that cannot be ruled out. 
 Liquid chromatography/MS-based approaches have been used in this study to track the 
changes in phospholipid metabolism that occur after zymosan addition to the macrophages. This 
technology offers great advantages, both at a qualitative and a quantitative level, over traditional 
methods that relied primarily on the use of radioactive precursors [71]. While the later kind of 
studies has been immensely useful to delineate pathways, intermediates and enzymes involved, 
radioactive tracers do not always distribute homogeneously among the various phospholipid 
pools, which has often led to inaccurate estimation of turnover rates [72, 73]. Actually, previous 
studies utilizing macrophages prelabeled with [3H]AA have shown that PE is a source of free AA 
when exposed to a variety of stimuli, including zymosan [57, 74-76]. These results contrast with 
our current mass measurements showing no changes in the AA content of all PE molecular 
species under activation conditions. Lack of apparent contribution of PE species to zymosan-
stimulated AA mobilization in macrophages as studied by mass spectrometry, has also been 
reported by other laboratories [2], and we have obtained the same result in zymosan-stimulated 
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human monocytes [33]. This discrepancy provides a germane example of the differences 
between using label or mass to determine sources of AA release in stimulated cells. However, a 
scenario that reconciles all these observations would be one where PE species are indeed 
substrates for cPLA2α-mediated AA mobilization but, once hydrolyzed by cPLA2α, they are 
rapidly re-formed with AA coming from other sources, namely PC via CoA-independent 
transacylation reactions. We tested this possibility by using SK&F98625, a well-established 
CoA-independent transacylase inhibitor [42, 43]. We found that in the presence of the inhibitor, 
marked decreases in the cellular levels of AA-containing PE species were measured which were 
accompanied by the corresponding increases in AA-containing PC species. Thus these results 
provide direct evidence that in zymosan-stimulated cells, the levels of AA-containing PE species 
are tightly controlled by the opposing actions of cPLA2α and CoA-independent transacylase.  
 A striking feature of this work is that inhibition by SK&F98625 of the transfer of AA 
from PC to PE leads to a strong increase of lipoxygenase metabolite formation in response to 
zymosan. From a biochemical point of view, the data are consistent with AA-containing PC 
molecules being the major precursors of lipoxygenase metabolites under zymosan stimulation, 
since blockade of CoA-independent transacylation by SKF98625 would favor the cPLA2α-
mediated cleavage of AA-containing PC over the AA transfer from PC to PE. This view is 
reminiscent of early work by Chilton suggesting that ether-linked PC species, which are major 
donors of AA in the CoA-independent transacylation reaction [54], are also important sources of 
AA used for lipoxygenase metabolite production in neutrophils [77]. More interestingly, these 
data are immediately relevant to innate immune signaling in that they unveil a previously 
unrecognized mechanism to protect against excessive production of certain eicosanoids during 
inflammation. Thus, by channeling the AA present in PC towards PE, the CoA-independent 
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transacylation reactions may limit lipoxygenase product formation under zymosan stimulation. 
While much data exists on the role cyclooxygenase products in regulating innate immune 
responses, the contribution of lipoxygenase products is less well appreciated. Relevant to the 
results of this study, increased amounts of  5-, 12-, and 15-HETE are synthesized when CoA-
independent transacylation is inhibited. These metabolites are known to interact with specific 
receptors on the surface of immune cells thereby impacting on intracellular signaling, and 
ultimately modulating various innate immune responses such as leukocyte migration or 
generation of other proinflammatory mediators [78-80].  
In addition to cPLA2α and iPLA2β, murine peritoneal macrophages are known to express 
another PLA2 form, i.e. the secreted group V enzyme, and this form has previously been shown 
to participate in zymosan-stimulated phospholipid turnover in these cells [81]. It is assumed that 
group V PLA2 participates in zymosan-induced signaling by directly hydrolyzing membrane 
phospholipids via its intrinsic enzymatic activity; however it has not been ruled out that the 
enzyme may also act as a surface receptor ligand in an activity-independent manner [81]. In any 
case, it has become clear over the years that secreted PLA2 enzymes act after cPLA2α by 
amplifying the response that the later enzyme initiates [8-11]. Therefore, it is conceivable that 
the contribution of group V PLA2 to phospholipid hydrolysis will be blocked if cPLA2α is 
inhibited. Thus, our pyrrophenone data would include the contribution of group V PLA2 to 
overall phospholipid hydrolysis. At present we have not been able to locate a reliable, reasonably 
selective and cell-permeable, group V PLA2 inhibitor. Thus we cannot directly examine the 
effect of group V PLA2 during zymosan stimulation of the macrophages. In the absence of such 
inhibitor, the use of macrophages isolated from group V PLA2 knockout animals could be 
envisioned as a useful alternative, especially because these cells do show reduced responses to 
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zymosan under certain conditions [82, 83]. However, aside from the potential pitfalls associated 
with the use of cells from knockout animals discussed above, a significant problem with the 
group V knockout mouse is that the effects observed depend on the genetic background of the 
animal; group V PLA2 null cells on a C57BL/6 genetic background show altered responses to 
stimuli but  group V PLA2 null cells on a BMMC background do not [84]. This argues again for 
the importance of developing potent and selective inhibitors for the various PLA2 forms, 
including group V PLA2, to more accurately assess the involvement of these key enzymes in 
regulating both physiological and pathophysiological processes. In this regard, the inhibitor 
studies reported in this study provide clues to understand the independent but coordinate 
regulation of phospholipid turnover in activated macrophages by two distinct PLA2s. 
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Figure Legends 
 
Figure 1. AA-containing phospholipid species in control and zymosan-stimulated macrophages. 
The cells were either unstimulated (open bars) or stimulated by 1 mg/ml zymosan in the absence 
(black bars) or presence of 1 µM FKGK18 (light gray bars) or 1 µM pyrrophenone (dark gray 
bars). After 1 h, the cellular content of  PC (A), PE (B) and PI (C) molecular species was 
determined by liquid chromatography/mass spectrometry.  FKGK18 and pyrrophenone exerted 
no effect on the unstimulated levels of any phospholipid species and these data have been 
omitted to make the figure clearer. The data are shown as means ± S.E.M. of three independent 
determinations. 
 
Figure 2. Effect of  SK&F98625 on the profile of AA-containing species in zymosan-stimulated 
macrophages. The cells were either unstimulated (open bars) or stimulated by 1 mg/ml zymosan 
in the absence (black bars) or presence (dark gray bars) of 10 µM SK&F98625. After 1 h, the 
cellular content of PC (A), and PE (B) molecular species was determined by liquid 
chromatography/mass spectrometry.  Incubations that received SK&F98625  but not zymosan 
are shown in light gray. The data are shown as means ± S.E.M. of three independent 
determinations. 
 
Figure 3. Effect of SK&F98625 on the profile of eicosanoids produced by zymosan-stimulated 
macrophages. The cells were either unstimulated (open bars) or stimulated with 1 mg/ml 
zymosan in the absence (black bars) or presence (dark gray bars) of 10 µM SK&F98625. After 8 
h, supernatants were collected and the production of cyclooxygenase (COX) (A) or lipoxygenase 
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(LOX) (B) metabolites was was determined by liquid chromatography/mass spectrometry. 
Incubations that received SK&F98625 but not zymosan are shown in light gray. The data are 
shown as means ± S.E.M. of three independent determinations. In the abscissa to panel B, tnr 
stands for tetranor. 
 
Figure 4. Phospholipid species not containing AA in control and zymosan-stimulated 
macrophages. The cells were either unstimulated (open bars) or stimulated by 1 mg/ml zymosan 
in the absence (black bars) or presence of 1 µM FKGK18 (light gray bars) or 1 µM 
pyrrophenone (dark gray bars). After 1 h, the cellular content of  PC (A), PE (B) and PI (C) 
molecular species was determined by liquid chromatography/mass spectrometry. FKGK18 and 
pyrrophenone had no significant effect on the unstimulated levels of any phospholipid species 
and these data have been omitted to make the figure clearer. The data are shown as means ± 
S.E.M. of three independent determinations. 
 
Figure 5. Lysophospholipid molecular species generated by zymosan-stimulated macrophages. 
The cells were either unstimulated (open bars) or stimulated by 1 mg/ml zymosan in the absence 
(black bars) or presence of 1 µM FKGK18 (light gray bars) or 1 µM pyrrophenone (dark gray 
bars). After 1 h, the cellular content of  lysoPC (A), lysoPE (B) and lysoPI (C) molecular species 
was determined by liquid chromatography/mass spectrometry. FKGK18 and pyrrophenone 
exerted no effect on the unstimulated levels of any lysophospholipid species and these data have 
been omitted to make the figure clearer. The data are shown as means ± S.E.M. of three 
independent determinations. 
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Figure 6. Phospholipid molecular species that initially incorporate [2H]AA. The cells were 
exposed to 1 µM [2H]AA at the time they were either unstimulated (open bars) or stimulated 
(filled bars) with 1 mg/ml zymosan for 30 min. The incorporation of [2H]AA was determined by 
liquid chromatography/mass spectrometry. The data are shown as means ± S.E.M. of three 
independent determinations. 
 
 
 
